Expired activity
Please go to the PowerPak homepage and select a course.

Managed Care Pharmacists’ Role in Chronic Management of Polyvascular Disease

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Medtelligence in collaboration with Postgraduate Institute for Medicine.

Annenberg Center for Health Sciences at Eisenhower Postgraduate Institute for Medicine Medtelligence

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Release date:

January 29, 2020

Expiration date:

January 29, 2021

Estimated time to complete the activity:

30 minutes

Program Overview

This live activity will feature nationally recognized leaders in managing anticoagulation in patients with coronary artery disease (CAD), peripheral artery disease (PAD) and venous thromboembolism (VTE) sharing the latest evidence and clinical practice pearls to managed care pharmacists. Discussion on the Managed Care Pharmacists role in chronic management of polyvascular disease will feature guidelines, economics and a pharmacy checklist on anticoagulation that will incorporate the guidelines, recent data, and managed care implications to give attendees an educated framework for their decision making in this area.

Target Audience

This activity is designed to meet the educational needs of managed care pharmacists, administrators and medical directors, physicians and nurses, national account managers, health economics and outcomes research staff.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Relate the clinical implications of anticoagulation in CAD, PAD, and VTE based on recent data
  • Utilize NOACs at the proper dose for patients with moderate or high risk of stroke, advising patients of the risks and benefits, and performing proper follow-up
  • Provide accurate and appropriate counsel as part of the treatment team


William E. Boden, MD, FACC, FAHA, Chair
Professor of Medicine
Boston University School of Medicine
Physician Research Lead & Scientific Director Clinical Trials Network
VA New England Healthcare System
VA Boston - Jamaica Plain Campus

Daniel E. Hilleman, PharmD
Professor and Director, Continuing Education
Creighton University School of Pharmacy and Health Professions

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Medtelligence. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

acpeThis program has been developed according to the ACPE Criteria for Quality and is assigned ACPE Universal Activity #0797-9999-20-003-H01-P. This program is designated for up to .50 contact hours (0.05 CEUs) of continuing pharmacy education credit.
Activity type: Knowledge

Disclosure of Conflicts of Interest

The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.


William E. Boden, MD, FACC, FAHA
Consulting Fees: CV Therapeutics, Sanofi Aventis, PDL Bio Pharma, KOS
Commercial Interest Speakers Bureau: CV Therapeutics, Sanofi Aventis, PDL, KOS, Pfizer, Merck

Daniel Hilleman, PharmD
Commercial Interest Speakers Bureau: Amgen

Planners and Managers

The PIM planners and managers have nothing to disclose. The Medtelligence planners and managers have nothing to disclose. Charles E. Willis, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose

Method of Participation and Request for Credit

There are no fees for participating and receiving CPE credit for this activity. During the period January 29, 2020 through January 29, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, complete the post-test and evaluation. Participants who successfully complete the activity, post-test, and evaluation will have a statement of credit made available immediately.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.



Required Computer Hardware/Software

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Additional information

For more information, contact Medtelligence at info@medtelligence.net.